{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-007404","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.459822+00:00","generated_at":"2026-06-20T02:35:08.223158+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive licenses Renazorb to Lotus for Korea; $0.75M upfront, up to $4.45M milestones","bullets":["Exclusive license to Lotus for Renazorb in Republic of Korea; Lotus handles development, registration, importation, and commercialization costs.","Unicycive receives $750,000 upfront and up to $4.45M in regulatory/commercial milestones plus tiered royalties.","Renazorb is a phosphate binding agent for hyperphosphatemia in CKD patients; this is Unicycive's second Asian partnership.","Lotus has nephrology presence in Korea via Alvogen Korea with 45% market share for Epoetin (IQVIA 3Q 2022)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-007404","json":"https://secwatch.observer/filing/0001213900-23-007404.json","markdown":"https://secwatch.observer/filing/0001213900-23-007404.md","text":"https://secwatch.observer/filing/0001213900-23-007404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/0001213900-23-007404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/ea172614-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T02:35:08.223158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bfe2c0851aa9b890319d0dff5b54e817029e05d","claim":"Unicycive Therapeutics, Inc. entered into License Agreement with Lotus International Pte Ltd. valued at $750,000 (effective 2023-02-01).","evidence_excerpt":"Unicycive Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) effective as of February 1, 2023 with Lotus International Pte Ltd. (“Lotus”) pursuant to which the Company licensed the exclusive right to develop, market and commercialize Renazorb® to Lotus in the Republic of Korea. Under the terms of the agreement, Lotus will be responsible for development, registration filing and approval for Renazorb® in the licensed territory. In addition, Lotus will have sole responsibility for the importation of the drug product from Unicycive and for the costs of commercialization of Renazorb® in the licensed territory. The Company will receive an upfront payment of $750,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023007404/0001213900-23-007404-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Lotus International Pte Ltd."},{"label":"Value","value":"$750,000"},{"label":"Effective","value":"2023-02-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}